- how is it just a small step forward to get your first reimbursed patients in a huge market? Wouldn’t you think proving up that you can access a market where the doctor gets paid, and patient doesn’t pay is a significant de-risking for the company?
- Might be worth going back over the multiple past presentations that explain why Australia is simply not a priority market for the company. Australia was only ever a test market, before launching in priority markets such as the US. The Aus market is not setup to launch new med-tech products of this nature (no ability for the doctor to get paid, no insurance reimbursement, patient pays - All of these key factors are the exact opposite of the US)
The market for this product is huge, and there are little to no direct competitors. As such, IMO, the most important thing to look for is evidence of product satisfaction from the perspective of the US doctors, patients, hospitals and insurers - tick all of these off, even at small scale, and the rest will take care of itself.
RSH Price at posting:
4.5¢ Sentiment: Buy Disclosure: Held
